Abstract nr
Head and Neck
Proffered Paper Session: Head and Neck Cancer
Chair: V. Gregoire (Belgium)
Chair: U. Keilholz (Germany)
10:30
2800
Cabazitaxel in patients with refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial UNICANCER ORL03
Speaker: J. Fayette (France)
10:45
2801
Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study
Speaker: C. Hsu (Taiwan)
11:00
2802
Phase II study of first-line paclitaxel (PTX) with panitumumab (P) in patients with metastatic or recurrent head and neck cancer: TTCC-2009-03 study
Speaker: J.C.A. Adansa Klain (Spain)
11:15
Discussant : U. Keilholz (Germany)
11:25
2803
Carbon ion radiotherapy for locally advanced parotid gland carcinomas
Speaker: M. Koto (Japan)
11:40
2804
Primary surgery for advanced oropharyngeal and hypopharyngeal cancers: A nationwide study in Taiwan
Speaker: C.T. Cheng (Taiwan)
11:55
2805
Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): An updated analysis
Speaker: L. Wirth (USA)
12:10
Discussant : V. Gregoire (Belgium)
12:20
10LBA
LATE BREAKING ABSTRACT: Final results of the prospective DDFMISO-trial validating hypoxia-specific PET imaging during radiochemotherapy for local control of locally advanced head-and-neck cancer
Speaker: M. Baumann (Germany)
12:30
11LBA
LATE BREAKING ABSTRACT: Differences in the quality of life (QoL) and functional outcomes of treatment between HPV associated (HPV+) and HPV- patients receiving primary chemoradiotherapy in PET-NECK – a multi-centre randomized phase III controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNC) treated with primary radical chemoradiotherapy (CRT)
Speaker: H. Mehanna (United Kingdom)
12:40
Discussant : S. Oosting (Netherlands)